Clinical Nuclear Medicine

Skip Navigation LinksHome > September 2012 - Volume 37 - Issue 9 > Metastatic Neuroendocrine Carcinoma Presenting as a “Supersc...
Clinical Nuclear Medicine:
doi: 10.1097/RLU.0b013e31825b1e6c
Interesting Images

Metastatic Neuroendocrine Carcinoma Presenting as a “Superscan” on 68Ga-DOTANOC Somatostatin Receptor PET/CT

Naswa, Niraj; Karunanithi, Sellam; Soundararajan, Ramya; Das, Kalpa Jyoti; Agarwal, Krishan Kant; Malhotra, Arun; Bal, Chandrasekhar; Kumar, Rakesh MD

Article Outline
Collapse Box

Author Information

From the Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.

Received for publication December 17, 2011; revision accepted April 12, 2012.

Conflicts of interest and sources of funding: none declared.

Reprints: Rakesh Kumar, MD, Department of Nuclear Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi-110029, Indica. E-mail: rkphulia@yahoo.com.

Collapse Box

Abstract

Abstract: PET/CT imaging using 68Ga-labeled somatostatin analogs has become a popular noninvasive diagnostic modality in the workup of patients with neuroendocrine tumors. A 65-year-old man with pancreatic neuroendocrine tumor with confirmed liver metastases on conventional imaging underwent restaging 68Ga-DOTANOC PET/CT to monitor response to cold octreotide therapy. Previous PET/CT had shown presence of multiple liver and skeletal metastases along with a primary pancreatic tumor showing intense tracer uptake. The present PET/CT study showed an increase in number and uptake of the metastatic lesions suggestive of progressive disease resulting in the appearance of a superscan.

Figure 1
Figure 1
Image Tools
Back to Top | Article Outline

REFERENCES

Figure 2
Figure 2
Image Tools
1. Lamberts SWJ, Krenning E, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrinol Rev. 1991: 12: 450–482.

2. Bombardieri E, Ambrosini V, Aktolun C, et al.. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010; 37: 1441–1448.

3. Virgolini I, Ambrosini V, Bomanji JB, et al.. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010; 37: 2004–2010.

4. Haug AR, Rominger A, Mustafa M, et al.. Treatment with octreotide does not reduce tumor uptake of 68Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors. J Nucl Med. 2011; 52: 1679–1683.

5. Kim SE, Kim DY, Lee DS, et al.. Absent of faint renal uptake in bone scan etiology and significance in metastatic bone disease. Clin Nucl Med. 1991; 16: 545–549.

6. Hain SF, Fogelman I. Nuclear medicine studies in metabolic bone disease. Semin Muskuloskelet Radiol. 2002; 6: 323–329.

7. Kim DW, Kim CG, Park SA, et al.. Metabolic super scan in 18F-FDG PET/CT imaging. J Korean Med Sci. 2010; 25: 1256–1257.

8. Liu RS, Chu YK, Chu LS, et al.. Superscan in patients with nasopharyngeal carcinoma. Clin Nucl Med. 1996; 21: 302–306.

Cited By:

This article has been cited 1 time(s).

Molecular Imaging and Biology
Effects of Chelator Modifications on Ga-68-Labeled [Tyr(3)]Octreotide Conjugates
Lin, M; Welch, MJ; Lapi, SE
Molecular Imaging and Biology, 15(5): 606-613.
10.1007/s11307-013-0627-x
CrossRef
Back to Top | Article Outline
Keywords:

neuroendocrine tumor; 68Ga-DOTANOC; PET/CT; superscan

© 2012 Lippincott Williams & Wilkins, Inc.

Login

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.